anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a compound represented by the general formula shown below, which can bind to a retinoid X receptor (RXR), which is one of nuclear receptors, and exhibit an agonistic or antagonistic action. [Wherein, R 1  is selected from the group consisting of an alkyl group, an alkenyl group, an alkynyl group and an aryl group. R 2  is selected from the group consisting of an alkoxy group, an alkyl group, an alkenyl group, an alkynyl group and an aryl group. W is NR 3  or CR 3 ; and R 3  is selected from a hydrogen, an alkyl group, an alkenyl group, an alkynyl group and an aryl group. X 1  and Y 1  are selected from CH or N. X 2  and Y 2  are selected from CH, CR 4  or N. R 4  is selected from an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a halogen, a nitro group and an amino group. Z is selected from a carboxylic acid, a carboxylate ester or a hydroxamic acid, which is bound directly or via an alkyl group, an alkenyl group or an alkynyl group.]
Disclosed is an AR self-injection training system and method of use incorporating a marker specifically designed for device-naive self-injection patients. The marker is designed so that it can be removably adhered to an injection site. Once in position it anchors AR content to the injection site for training. The marker is designed to associate AR content to the injection site for training and allows patient to leave the marker in place and inject to the same site. Providing a system that is able to identify a site of injection and to provide salient instructions streamlines the process of training and makes the transition to using a real-device relatively seamless. The provided embodiments can also incorporate error correction functionality and even local anesthesia or analgesic. Following training, the opening in the marker allows patients to leave the marker in place and inject to the same site.
Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
NEW MATERIAL:A growth hormone of fish of Percichthyidae family composed of a polypeptide having the following properties. Amino acid composition, ASP 18, Thr 58, Ser 20.8, Glu 26.4, etc.; amino acid sequence of C terminal, shown in the formula; molecular weight, 23,000; isoelectric point, 7.5; solubility, soluble in basic aqueous solution and hardly soluble or insoluble in neutral and acidic aqueous solution. USE:Growth promotion agent for fish of Percichthyidae family (e.g. common sea bass) and Clupidae family (e.g. herring). PREPARATION:For example, the pituitary gland of yellowfin tuna is ground together with ice-cooled acetone and centrifuged in frozen state to remove the supernatant liquid. The residue is ground together with ice-cooled aqueous solution of phenylmethylsulfonyl fluoride and EDTA and extracted with an aqueous solution of NaOH under ice-cooling and agitation. The treated product is subjected to freezing centrifugation and the separated supernatant liquid is dialyzed and freeze-dried. The obtained powder is purified e.g. by sephadex column chromatography.
Long-term exposure to non-physiologically compatible dialysate inevitably leads to peritoneal fibrosis (PF) in patients undergoing peritoneal dialysis (PD), and there is no effective prevention or treatment for PF. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid produced after catalysis by sphingosine kinase (SPHK) 1/2 and activates signals through the S1P receptor (S1PR) via autocrine or paracrine. However, the role of SPHK1/S1P/S1PR signaling has never been elucidated in PF. In our research, we investigated S1P levels in peritoneal effluents and demonstrated the role of SPHK1/S1P/S1PR pathway in peritoneal fibrosis. It was found that S1P levels in peritoneal effluents were positively correlated with D/P Cr (r = 0.724, p < .001) and negatively correlated with 4 h ultrafiltration volume (r = -0.457, p < .001). S1PR1 and S1PR3 on peritoneal cells were increased after high glucose exposure in vivo and in vitro. Fingolimod was applied to suppress S1P/S1PR pathway. Fingolimod restored mouse peritoneal function by reducing interstitial hyperplasia, maintaining ultrafiltration volume, reducing peritoneal transport solute rate, and mitigating the protein expression changes of fibronectin, vimentin, α-SMA, and E-cadherin induced by PD and S1P. Fingolimod preserved the morphology of the human peritoneal mesothelial cells, MeT-5A, and moderated the mesothelial-mesenchymal transition (MMT) process. We further delineated that SPHK1 was elevated in peritoneal cells after high glucose exposure and suppression of SPHK1 in MeT-5A cells reduced S1P release. Overexpression of SPHK1 in MeT-5A cells increased S1P levels in the supernatant and fostered the MMT process. PF-543 treatment, targeting SPHK1, alleviated deterioration of mouse peritoneal function. In conclusion, S1P levels in peritoneal effluent were correlated with the deterioration of peritoneal function. SPHK1/S1P/S1PR pathway played an important role in PF.
The invention belongs to the field of biomedicine, and relates to a preparation method of an external preparation of an artemisia apiacea sesquiterpene extract and application of the external preparation in preventing and treating inflammatory skin diseases such as eczema and acne. The content of 5 sesquiterpene components of the quantifiable artemisinin, the arteannuin, the dihydroarteannuin, the arteannuin I and the arteannuin in the raw material medicines is more than 50 percent, and the content of 2 flavonoid components of the quantifiable castanopsis japonica Jing Suji Ai Huangsu is about 1.5 percent. The raw material medicines are added with pharmaceutically acceptable auxiliary materials to prepare the external preparation for treating inflammatory dermatosis such as eczema and acne. The external preparation has effects of regulating skin inflammation and relieving edema, and has good effects of relieving or even eliminating symptoms such as erythema, pruritus, swelling, skin tightening, etc. caused by inflammatory dermatoses. Compared with the treatment modes of oral chemical drugs, biological preparations and the like, the anti-inflammatory preparation has better compliance for external application.
The invention discloses a hydrogen peroxide response metal polyphenol capsule carrier. The carrier is used for encapsulating drug loading, and the capsule carrier is constructed by EGCG, fucoidin and divalent manganese ions by taking calcium carbonate as a sacrificial template. The size of the metal polyphenol capsule carrier reaches submicron level, the drug loading rate and the encapsulation rate reach the standard, the intelligent hydrogen peroxide responds, and the blood compatibility is excellent. The urokinase encapsulated capsule has the following advantages in the aspect of thrombus treatment: 1. can accurately identify thrombus, release urokinase at fixed points, eliminate thrombus and reduce the occurrence of uncontrollable bleeding. 2. The hydrogen peroxide is eliminated to relieve the inflammatory thrombus microenvironment, and the thrombolysis is effectively cooperated with urokinase.
Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs. 

4 mg per 100 mL Single-Use Ready-to-Use Bottle 

Bottles of zoledronic acid injection ready-to-use solution for infusion contain overfill allowing for the administration of 100 mL of solution (equivalent to 4 mg zoledronic acid). This solution is ready-to-use and may be administered directly to the patient without further preparation. For single-use only.

To prepare reduced doses for patients with baseline CrCl less than or equal to 60 mL/min, withdraw the specified volume of the zoledronic acid injection solution from the bottle (see Table 2) and replace with an equal volume of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP. Administer the newly-prepared dose-adjusted solution to the patient by infusion. Follow proper aseptic technique. Properly discard previously withdrawn volume of ready-to-use solution - do not store or reuse.

Table 2: Preparation of Reduced Doses – Zoledronic Acid Injection ready-to-use-bottle

If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C - 8°C (36°F - 46°F). The refrigerated solution should then be equilibrated to room temperature prior to administration. The total time between dilution, storage in the refrigerator, and end of administration must not exceed 24 hours.
ALIF is a commonly performed procedure for the treatment of degenerative diseases of the lumbar spine or spondylolisthesis. This technique has many advantages attributed to the absence of posterior spinal muscular pain, a more direct visualization of the disk space, lower incidence of neurological injuries... However, patients experienced moderate to high post operative parietal abdominal pain due to this specific anterior approach. The systematic need for opioids administration may cause many complications and delay the post operative recovery time. The TAP block has been described as an effective pain control technique after various lower abdominal surgeries, reducing both pain scores and 24 hours opioids consumption. However the analgesic efficacy of this technique on specific parietal abdominal pain experienced after spine surgery by anterior approach is not clear
Rationale: Bronchiectasis is a pathological dilatation of the bronchi in the respiratory airways associated with environmental or genetic causes (e.g., cystic fibrosis, primary ciliary dyskinesia, and primary immunodeficiency disorders), but most cases remain idiopathic. Objectives: To identify novel genetic defects in unsolved cases of bronchiectasis presenting with severe rhinosinusitis, nasal polyposis, and pulmonary Pseudomonas aeruginosa infection. Methods: DNA was analyzed by next-generation or targeted Sanger sequencing. RNA was analyzed by quantitative PCR and single-cell RNA sequencing. Patient-derived cells, cell cultures, and secretions (mucus, saliva, seminal fluid) were analyzed by Western blotting and immunofluorescence microscopy, and mucociliary activity was measured. Blood serum was analyzed by electrochemiluminescence immunoassay. Protein structure and proteomic analyses were used to assess the impact of a disease-causing founder variant. Measurements and Main Results: We identified biallelic pathogenic variants in WAP four-disulfide core domain 2 (WFDC2) in 11 individuals from 10 unrelated families originating from the United States, Europe, Asia, and Africa. Expression of WFDC2 was detected predominantly in secretory cells of control airway epithelium and also in submucosal glands. We demonstrate that WFDC2 is below the limit of detection in blood serum and hardly detectable in samples of saliva, seminal fluid, and airway surface liquid from WFDC2-deficient individuals. Computer simulations and deglycosylation assays indicate that the disease-causing founder variant p.Cys49Arg structurally hampers glycosylation and, thus, secretion of mature WFDC2. Conclusions: WFDC2 dysfunction defines a novel molecular etiology of bronchiectasis characterized by the deficiency of a secreted component of the airways. A commercially available blood test combined with genetic testing allows its diagnosis.
BACKGROUND: Kidney stone disease (KSD) is a prevalent and significant global urological issue, and ureteroscopic holmium laser lithotripsy (UHLL) is a primary treatment option. This study aimed to assess the impact of stone computed tomography (CT) value on the outcomes of UHLL in treating KSD.
METHODS: A retrospective analysis was conducted on the clinical data of 101 patients who underwent UHLL at our hospital between September 2022 and December 2023. Patients were categorised into two groups based on stone CT values. Demographic characteristics, intraoperative factors, stone clearance, and complications were evaluated and compared between the low- and high-CT groups.
RESULTS: The high-CT group had significantly longer intraoperative durations than the low-CT group (p < 0.001). Fragmentation time was considerably higher in the high-CT group (p < 0.001). Stone clearance rates after three postoperative months were substantially higher in the low-CT group (98.04%) than in the high-CT group (84.00%) (χ2 = 4.523, p = 0.033). Although the low-CT group had a lower complication rate, the difference was insignificant (p = 0.356). CT values showed a positive correlation with durations of operation and fragmentation (p < 0.01), and a negative correlation with stone clearance (p < 0.05).
CONCLUSIONS: Stone CT values are key factors influencing the procedural outcomes and postoperative complications of UHLL.
Cerebral Palsy (CP) is the most common developmental disorder in childhood. Individuals' independence in daily living activities and participation in education, games, social and community activities are restricted. Technology applications in the field of rehabilitation are gaining momentum. EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities. Therefore, the aim of our study is to examine the acute effect of Mollii Suit application on balance and muscle tone problems in children with spastic cerebral palsy.
The invention relates to a local anesthetic which is a fat-emulsion-emulsified local anesthetic. According to the invention, the local anesthetic is dissolved in a fat-emulsion, and the solution is a medicine used in local anesthesia such as nerve blocking anesthesia, intraspinal anesthesia, local infiltration anesthesia and local intravenous anesthesia. According to the invention, the fat emulsion and the local anesthetic are processed through heating, oscillating, stirring, homogenizing, and the like, such that the local anesthetic is prepared. With the fat-emulsion-emulsified local anesthetic, original local anesthetic potency is ensured; the toxic reaction limit dose of the local anesthetic is greatly increased, and the severity of happened toxic reaction is reduced. Therefore, patient security is improved. Also, the production process of the medicine is simple, and the price is low.
OBJECTIVE: To investigate the associations between brain magnetic resonance imaging (MRI) changes and clinical profiles in children with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
METHODS: Clinical data and brain MRI results of children diagnosed with anti-NMDAR encephalitis in Guangzhou Women and Children's Medical Center from October 2014 to June 2022 were retrospectively studied.
RESULTS: A total of 143 children (Male: female 54:89) were enrolled, with a mean onset age of 6.8 years (6.8 ± 3.1). 40.6 % (58/143) of patients had abnormal initial brain MRI. Lesions in temporal lobe (34.5 %, 20/58) and frontal lobe (25.9 %, 15/58) were relatively common. Children with abnormal initial brain MRI were prone to have fever (P = 0.023), dystonia (P = 0.037), positive MOG antibodies (P = 0.015), higher cerebrospinal fluid (CSF) white blood cell count (WBC) (P = 0.019) and to receive rituximab treatment (P = 0.037). There were no significant differences in modified Rankin Scale (mRS) scores before immunotherapy, after immunotherapy and at last follow-up between the normal initial brain MRI group and abnormal group. No initial brain MRI changes were found to be associated with relapses. Brain MRI was reviewed in 72 patients at last follow-up with a median follow-up time of 25.5 months and 48.6 % (35/72) of patients had abnormal brain MRI. The mRS score of the group with normal brain MRI at last follow-up was significantly lower than that of the abnormal group.
CONCLUSIONS: About 40.0 % of children with anti-NMDAR encephalitis had abnormal initial brain MRI. Initial brain MRI was associated with certain clinical profiles, but not with relapse and prognosis. Around half of patients had abnormal brain MRI at last follow-up and were prone to have higher mRS score.
Patients who meet DSM-IV criteria for major depression(using the SCID),have a Hamilton Depression Rating Scale score of at least 18, and who are not complete responders to antidepressant medications will be invited to participate in an open label study with pramipexole. Patients who are not complete responders to an adequate trial of an antidepressant (see inclusion criteria below) will be openly treated with pramipexole for 8 weeks. Participants must be between the ages of 20-55 and will include both men and women. Patient's mood will be assessed each visit using the Hamilton Depression (HDRS) and will also complete a series of questionnaires. This will include the physical and social anhedonia scales (Chapman et al., 1976; Eckblad et al., 1982), the Snaith-Hamilton Pleasure Scale (SHAPS; Franken et al., 2007; Snaith et al., 1995), the Mood and Anxiety Symptom Questionnaire Short Form (MASQ; Watson, Weber, et al., 1995; Watson, Clark, et al., 1995), and the Positive and Negative Affect Scale (Watson \& Clark, 1991)among others. No other adjunctive agents will be allowed during the eight weeks of the study. Patients will be seen for four weeks on a weekly basis, then biweekly thereafter.

Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (\> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.

Depressed participants will also undergo functional MRI and neuropsychological testing twice, once at baseline and once after completion of the medication. 20 healthy control subjects with no history of Axis I disorders and who score less than 5 on the HDRS will participate in the baseline MRI, neuropsychological testing, and clinical ratings/questionnaires.
Patients who experienced severe forms of COVID-19 during the first wave, without any prior vaccination, selected from the pre-existing NOSO-COR IMMUNO cohort (ClinicalTrial no. NCT04637867).
The invention belongs to the technical field of traditional Chinese medicine pharmacy, and provides a method for extracting anti-inflammatory and antioxidant components of fructus forsythiae. The extraction solvent can be used for preparing oral preparation of fructus forsythiae. Mixing polyalcohol and choline quaternary ammonium salt at a molar ratio of 4-1:1, heating at 90 deg.C to obtain DES liquid, and diluting the DES liquid to obtain extractive solvent for extracting antiinflammatory and antioxidant components from fructus forsythiae fruit powder. The fructus forsythiae extract has no cytotoxicity and good antiinflammatory and antioxidant effects. The invention uses a novel solvent to extract the traditional Chinese medicine, optimizes the extraction process and evaluates the biological activity of the extracting solution at the cell level. Has important significance for the development and the application of forsythia oral liquid preparations.
Participants will be given daily glucose monitoring goals of ≥4 glucose checks per day with ≥1 readings within goal range (70-180 mg/dL) and provided with iHealth wireless glucometers. Half of the study participants will be randomized to the 3-month intervention arm on Way to Health. The intervention includes daily financial incentives ($60 in an account at beginning of each month with $2 daily loss if non-adherent) and a 2-level tiered sponsor network (youth select 2 people who will be notified of non-adherence after 2 and 5 consecutive days). The primary outcome will be HbA1c at 3 months compared to baseline. Secondary outcomes will include HbA1c at 6 months and the proportion of participants adherent to daily glucose monitoring goals. Exit interviews will elicit intervention feasibility and feedback from a youth perspective.
The present invention relates to water-dispersible tablets of lamotrigine and pharmaceutically acceptable acid addition salts thereof. The water-dispersible tablet includes granules or compacts. The granules or compacts include lamotrigine or a pharmaceutically acceptable salt thereof and one or more disintegrants. The one or more disintegrants are not swellable clay disintegrants. The tablet is capable of dispersing in water within a period of three minutes to provide a dispersion which is capable of passing through a sieve screen with a mesh aperture of 710 μm in accordance with the test for dispersible tablets defined in British Pharmacopoeia 1988, volume II, page 895. The invention also relates to processes for the preparation of such tablets.
Investigate the effect of challenge of non-fava beans diet on occurrence of hemolysis in both common and rare mutations causing G6PD deficiency in Egyptian children as well as making a genotype-phenotype correlation. Patients and Methods: The study will include all G6PD deficient children who were regularly followed up in Pediatric Hematology Center, Ain Shams University over last decade from 2004-2014 who stopped eating non fava-bean diet since their diagnosis as G6PD deficient and willing to participate in the diet challenge. They will be enrolled in a one year prospective study involving quantitative analyses for enzymatic activity, and molecular typing of G6PD enzyme using a polymerase chain reaction-amplification refractory mutation system (PCR-ARMS) technique. Patient's medical records will be reviewed as history of blood transfusion and G6PD level at diagnosis. Initial phase will be dietetic challenge with ingestion of non-fava beans taken in small amount (10-20 gm/day for 3 successive days ) for children with haemoglobin level ≥ 11 gm/dl with daily clinical and laboratory monitoring by complete blood count, and markers of hemolysis as well as measurement of malondialdehyde (MDA) level both basal and at study end. A drop of Hb of ≥0.5 gm/dl and / or appearance of hemoglobinuria is considered a significant hemolysis. Patients who will not meet the definition of significant hemolysis will be prospectively followed up for one year with follow up during their chronic exposure by complete blood count and hemolysis markers/ 3 months.